{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["DNA damage", "anti-angiogenesis", "apoptosis", "hepatocellular carcinoma", "rotundic acid"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "31293977", "DateRevised": {"Year": "2020", "Month": "09", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "06", "Day": "26"}], "Language": ["eng"], "ELocationID": ["545", "10.3389/fonc.2019.00545"], "Journal": {"ISSN": "2234-943X", "JournalIssue": {"Volume": "9", "PubDate": {"Year": "2019"}}, "Title": "Frontiers in oncology", "ISOAbbreviation": "Front Oncol"}, "ArticleTitle": "Rotundic Acid Induces DNA Damage and Cell Death in Hepatocellular Carcinoma Through AKT/mTOR and MAPK Pathways.", "Pagination": {"StartPage": "545", "MedlinePgn": "545"}, "Abstract": {"AbstractText": ["Hepatocellular carcinoma (HCC) is the fourth largest cause of cancer-related deaths worldwide with limited therapeutic interventions. Renewed interest in natural products as drug leads has resulted in a paradigm shift toward the rapid screening of medicinal plants for the discovery of new chemical entities. Rotundic acid (RA), a plant-derived triterpenoid, has been anecdotally reported to possess anti-inflammatory and cardio-protective abilities. The present study highlights the anti-cancer efficacy of RA on HCC <i>in vitro</i> and <i>in vivo</i>. The inhibitory effects of RA on HCC cell viability was determined by MTT. Soft agar colony formation and clonogenic assays also showed that RA inhibited HCC cell proliferation. Flow cytometry, confocal, and western blot results further indicated that RA induced cell cycle arrest, DNA damage, and apoptosis by modulating the AKT/mTOR and MAPK pathways. Besides the suppression of migration and invasion, tube formation and VEGF-ELISA revealed the anti-angiogenic abilities of RA on HCC. Moreover, RA also inhibited tumor growth in a HepG2 xenograft mouse model. To our best knowledge, this is the first extensive study of the anticancer activity of RA on HCC. The results demonstrate that RA could be a potential drug candidate for HCC treatment."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China."}], "LastName": "Roy", "ForeName": "Gaurab", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China."}], "LastName": "Guan", "ForeName": "Su", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China."}], "LastName": "Liu", "ForeName": "Hexiang", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China."}, {"Identifier": [], "Affiliation": "Guangdong Provincial Engineering and Technological Centre for Biopharmaceuticals, South China University of Technology, Guangzhou, China."}], "LastName": "Zhang", "ForeName": "Lei", "Initials": "L"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Oncol", "NlmUniqueID": "101568867", "ISSNLinking": "2234-943X"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394\u2013424. 10.3322/caac.21492", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. . Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. (2005) 92:1862\u20138. 10.1038/sj.bjc.6602590", "ArticleIdList": ["10.1038/sj.bjc.6602590", "PMC2361778", "15870713"]}, {"Citation": "Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, et al. . Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol. (2016) 7:428. 10.3389/fphar.2016.00428", "ArticleIdList": ["10.3389/fphar.2016.00428", "PMC5101236", "27881963"]}, {"Citation": "Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology. (2009) 50:1140\u201351. 10.1002/hep.23118", "ArticleIdList": ["10.1002/hep.23118", "19711426"]}, {"Citation": "Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. (2017) 12:243\u201353. 10.1007/s11523-017-0484-7", "ArticleIdList": ["10.1007/s11523-017-0484-7", "28299600"]}, {"Citation": "Heo YA, Syed YY. Regorafenib: a review in hepatocellular carcinoma. Drugs. (2018) 78:951\u20138. 10.1007/s40265-018-0932-4", "ArticleIdList": ["10.1007/s40265-018-0932-4", "29915898"]}, {"Citation": "Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. (2013) 49:3412\u20139. 10.1016/j.ejca.2013.05.028", "ArticleIdList": ["10.1016/j.ejca.2013.05.028", "23809766"]}, {"Citation": "Frenette CT. The role of regorafenib in hepatocellular carcinoma. Gastroenterol Hepatol. (2017) 13:122\u20134.", "ArticleIdList": ["PMC5402683", "28450818"]}, {"Citation": "Ch'ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol. (2015) 7:2029\u201340. 10.4254/wjh.v7.i16.2029", "ArticleIdList": ["10.4254/wjh.v7.i16.2029", "PMC4528276", "26261692"]}, {"Citation": "Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol. (2012) 18:498\u2013506. 10.3748/wjg.v18.i6.498", "ArticleIdList": ["10.3748/wjg.v18.i6.498", "PMC3280394", "22363115"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. (2016) 79:629\u201361. 10.1021/acs.jnatprod.5b01055", "ArticleIdList": ["10.1021/acs.jnatprod.5b01055", "26852623"]}, {"Citation": "Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. (2009) 10:194\u2013200. 10.1038/embor.2009.12", "ArticleIdList": ["10.1038/embor.2009.12", "PMC2658564", "19229284"]}, {"Citation": "Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M, et al. . Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma. J Ethnopharmacol. (2013) 149:601\u201312. 10.1016/j.jep.2013.07.030", "ArticleIdList": ["10.1016/j.jep.2013.07.030", "23916858"]}, {"Citation": "Zhou Y, Li Y, Zhou T, Zheng J, Li S, Li HB. Dietary natural products for prevention and treatment of liver cancer. Nutrients. (2016) 8:156. 10.3390/nu8030156", "ArticleIdList": ["10.3390/nu8030156", "PMC4808884", "26978396"]}, {"Citation": "Fan Z, Zhou L, Xiong T, Zhou J, Li Q, Tan Q, et al. . Antiplatelet aggregation triterpene saponins from the barks of Ilex rotunda. Fitoterapia. (2015) 101:19\u201326. 10.1016/j.fitote.2014.11.007", "ArticleIdList": ["10.1016/j.fitote.2014.11.007", "25447155"]}, {"Citation": "Chinese Pharmacopoeia Commission Pharmacopoeia of the People's Republic of China, Vol. I. Beijing: China Medical Science Press; (2010)."}, {"Citation": "Kim YJ, Jung EB, Lee MS, Seo SJ, Kim MH, Lee MW, et al. . Rotundarpene inhibits toll-like receptor 2 activation-induced production of inflammatory mediators in keratinocytes by suppressing the Akt and NF-\u03baB pathways. Int Immunopharmacol. (2014) 18:325\u201332. 10.1016/j.intimp.2013.12.016", "ArticleIdList": ["10.1016/j.intimp.2013.12.016", "24378401"]}, {"Citation": "Yang B, Li H, Ruan QF, Xue YY, Cao D, Zhou XH, et al. . A facile and selective approach to the qualitative and quantitative analysis of triterpenoids and phenylpropanoids by UPLC/Q-TOF-MS/MS for the quality control of Ilex rotunda. J Pharm Biomed Anal. (2018) 157:44\u201358. 10.1016/j.jpba.2018.05.002", "ArticleIdList": ["10.1016/j.jpba.2018.05.002", "29758469"]}, {"Citation": "Hsu YM, Hung YC, Hu L, Lee YJ, Yin MC. Anti-diabetic effects of madecassic acid and rotundic acid. Nutrients. (2015) 7:10065\u201375. 10.3390/nu7125512", "ArticleIdList": ["10.3390/nu7125512", "PMC4690064", "26633490"]}, {"Citation": "He YF, Nan ML, Sun JM, Meng ZJ, Li W, Zhang M. Design, synthesis and cytotoxicity of cell death mechanism of rotundic acid derivatives. Bioorg Med Chem Lett. (2013) 23:2543\u20137. 10.1016/j.bmcl.2013.03.005", "ArticleIdList": ["10.1016/j.bmcl.2013.03.005", "23558236"]}, {"Citation": "Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, et al. . Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clin Cancer Res. (2014) 20:1274\u201387. 10.1158/1078-0432.CCR-12-3909", "ArticleIdList": ["10.1158/1078-0432.CCR-12-3909", "PMC4284945", "24520095"]}, {"Citation": "Bhat UG, Pandit B, Gartel AL. ARC synergizes with ABT-737 to induce apoptosis in human cancer cells. Mol Cancer Ther. (2010) 9:1688\u201396. 10.1158/1535-7163.MCT-09-0919", "ArticleIdList": ["10.1158/1535-7163.MCT-09-0919", "PMC2902270", "20515947"]}, {"Citation": "Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, et al. . Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA. (2005) 102:10528\u201333. 10.1073/pnas.0504367102", "ArticleIdList": ["10.1073/pnas.0504367102", "PMC1180792", "16024725"]}, {"Citation": "Meng J, Liu Y, Han J, Tan Q, Chen S, Qiao K, et al. . Hsp90\u03b2 promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma. Mol Cancer. (2017) 16:72. 10.1186/s12943-017-0640-9", "ArticleIdList": ["10.1186/s12943-017-0640-9", "PMC5374580", "28359326"]}, {"Citation": "Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC. p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res. (2008) 68:476\u201382. 10.1158/0008-5472.CAN-07-1960", "ArticleIdList": ["10.1158/0008-5472.CAN-07-1960", "PMC2376045", "18199542"]}, {"Citation": "Taddei ML, Parri M, Angelucci A, Bianchini F, Marconi C, Giannoni E, et al. . EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res. (2011) 9:149\u201360. 10.1158/1541-7786.MCR-10-0298", "ArticleIdList": ["10.1158/1541-7786.MCR-10-0298", "21205836"]}, {"Citation": "Tan XW, Xia H, Xu JH, Cao JG. Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gen-difluoromethylenechrysin. World J Gastroenterol. (2009) 15:2234\u20139. 10.3748/wjg.15.2234", "ArticleIdList": ["10.3748/wjg.15.2234", "PMC2682238", "19437563"]}, {"Citation": "Li DH, Li JY, Xue CM, Han T, Sai CM, Wang KB, et al. . Antiproliferative dimeric aporphinoid alkaloids from the roots of thalictrum cultratum. J Nat Prod. (2017) 80:2893\u2013904. 10.1021/acs.jnatprod.7b00387", "ArticleIdList": ["10.1021/acs.jnatprod.7b00387", "29131616"]}, {"Citation": "Zhou C, Qian L, Ma H, Yu X, Zhang Y, Qu W, et al. . Enhancement of amygdalin activated with \u03b2-D-glucosidase on HepG2 cells proliferation and apoptosis. Carbohydr Polym. (2012) 90:516\u201323. 10.1016/j.carbpol.2012.05.073", "ArticleIdList": ["10.1016/j.carbpol.2012.05.073", "24751072"]}, {"Citation": "DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ, et al. . Endothelial cell tube formation assay for the in vitro study of angiogenesis. J Vis Exp. (2014) e51312. 10.3791/51312", "ArticleIdList": ["10.3791/51312", "PMC4540586", "25225985"]}, {"Citation": "Zhang K, Chow PK. The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res. (2004) 10:5226\u201332. 10.1158/1078-0432.CCR-04-0061", "ArticleIdList": ["10.1158/1078-0432.CCR-04-0061", "15297426"]}, {"Citation": "Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science. (2009) 325:161\u20135. 10.1126/science.1168243", "ArticleIdList": ["10.1126/science.1168243", "19589993"]}, {"Citation": "McChesney JD, Venkataraman SK, Henri JT. Plant natural products: back to the future or into extinction? Phytochemistry. (2007) 68:2015\u201322. 10.1016/j.phytochem.2007.04.032", "ArticleIdList": ["10.1016/j.phytochem.2007.04.032", "17574638"]}, {"Citation": "Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. (2005) 78:431\u201341. 10.1016/j.lfs.2005.09.012", "ArticleIdList": ["10.1016/j.lfs.2005.09.012", "16198377"]}, {"Citation": "Butler MS, Newman DJ. Mother Nature's gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery. Prog Drug Res. (2008) 65:3\u201344. 10.1007/978-3-7643-8117-2_1", "ArticleIdList": ["10.1007/978-3-7643-8117-2_1", "18084912"]}, {"Citation": "Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. (2009) 20:880\u201392. 10.1097/CAD.0b013e328330fd90", "ArticleIdList": ["10.1097/CAD.0b013e328330fd90", "19745720"]}, {"Citation": "Sandh\u00f6fer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groi\u00df V, et al. . Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. (2015) 29:828\u201338. 10.1038/leu.2014.305", "ArticleIdList": ["10.1038/leu.2014.305", "25322685"]}, {"Citation": "Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. (2014) 90:197\u2013207. 10.1016/j.bcp.2014.05.011", "ArticleIdList": ["10.1016/j.bcp.2014.05.011", "24863259"]}, {"Citation": "Polivka J, Jr., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. (2014) 142:164\u201375. 10.1016/j.pharmthera.2013.12.004", "ArticleIdList": ["10.1016/j.pharmthera.2013.12.004", "24333502"]}, {"Citation": "Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. (2010) 19:919\u201330. 10.1517/13543784.2010.499121", "ArticleIdList": ["10.1517/13543784.2010.499121", "20569080"]}, {"Citation": "LoRusso PM. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. J Clin Oncol. (2016) 34:3803\u201315. 10.1200/JCO.2014.59.0018", "ArticleIdList": ["10.1200/JCO.2014.59.0018", "PMC6366304", "27621407"]}, {"Citation": "Burris HA, 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. (2013) 71:829\u201342. 10.1007/s00280-012-2043-3", "ArticleIdList": ["10.1007/s00280-012-2043-3", "23377372"]}, {"Citation": "Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. (2005) 103:307\u201312. 10.1002/cncr.20774", "ArticleIdList": ["10.1002/cncr.20774", "15593087"]}, {"Citation": "Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. . Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. (2011) 140:1071\u201383. 10.1053/j.gastro.2010.12.006", "ArticleIdList": ["10.1053/j.gastro.2010.12.006", "PMC3057329", "21147110"]}, {"Citation": "Zhang X, Yang H, Yue S, He G, Qu S, Zhang Z, et al. . The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. Cancer Med. (2017) 6:1941\u201351. 10.1002/cam4.1127", "ArticleIdList": ["10.1002/cam4.1127", "PMC5548872", "28675698"]}, {"Citation": "Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. . Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. (2008) 135:1972\u201383.e1\u201311. 10.1053/j.gastro.2008.08.008", "ArticleIdList": ["10.1053/j.gastro.2008.08.008", "PMC2678688", "18929564"]}, {"Citation": "Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, et al. . Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. (2007) 83:425\u201332. 10.1097/01.tp.0000252780.42104.95", "ArticleIdList": ["10.1097/01.tp.0000252780.42104.95", "17318075"]}, {"Citation": "Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. (2004) 10:8421\u20135. 10.1158/1078-0432.CCR-04-0941", "ArticleIdList": ["10.1158/1078-0432.CCR-04-0941", "15623621"]}, {"Citation": "Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, et al. . Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. (2008) 7:1789\u201396. 10.1158/1535-7163.MCT-08-0124", "ArticleIdList": ["10.1158/1535-7163.MCT-08-0124", "PMC2587125", "18644991"]}, {"Citation": "Yang Z, Xie H, He D, Li L. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling. Oncotarget. (2016) 7:44478\u201391. 10.18632/oncotarget.9873", "ArticleIdList": ["10.18632/oncotarget.9873", "PMC5190112", "27283897"]}, {"Citation": "De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. (2012) 16 (Suppl. 2):S17\u201327. 10.1517/14728222.2011.639361", "ArticleIdList": ["10.1517/14728222.2011.639361", "22443084"]}, {"Citation": "Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. (2000) 275:35778\u201385. 10.1074/jbc.M004267200", "ArticleIdList": ["10.1074/jbc.M004267200", "10958792"]}, {"Citation": "Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, Jung JS, et al. Role of ERK activation in cis platin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol. (2005) 25:374\u201382. 10.1002/jat.1081", "ArticleIdList": ["10.1002/jat.1081", "16013042"]}, {"Citation": "Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, et al. . ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. (2007) 26:2856\u201367. 10.1038/sj.emboj.7601723", "ArticleIdList": ["10.1038/sj.emboj.7601723", "PMC1894764", "17525735"]}, {"Citation": "Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. . Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. (2003) 22:6785\u201393. 10.1038/sj.onc.1206792", "ArticleIdList": ["10.1038/sj.onc.1206792", "14555991"]}, {"Citation": "Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. (2013) 4:342\u201359. 10.1177/1947601913507951", "ArticleIdList": ["10.1177/1947601913507951", "PMC3863344", "24349632"]}, {"Citation": "Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. (2001) 6:469\u201377. 10.1023/A:1012437607881", "ArticleIdList": ["10.1023/A:1012437607881", "11595837"]}, {"Citation": "Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. (2004) 10:125\u20139. 10.1016/j.molmed.2004.01.007", "ArticleIdList": ["10.1016/j.molmed.2004.01.007", "15102355"]}, {"Citation": "Xing W, Chen DT, Pan JH, Chen YH, Yan Y, Li Q, et al. . Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology. (2017) 126:868\u201381. 10.1097/ALN.0000000000001528", "ArticleIdList": ["10.1097/ALN.0000000000001528", "28121635"]}, {"Citation": "Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence. FEBS J. (2010) 277:2\u201321. 10.1111/j.1742-4658.2009.07366.x", "ArticleIdList": ["10.1111/j.1742-4658.2009.07366.x", "19843174"]}, {"Citation": "El Mchichi B, Hadji A, Vazquez A, Leca G. p38 MAPK and MSK1 mediate caspase-8 activation in manganese-induced mitochondria-dependent cell death. Cell Death Differ. (2007) 14:1826\u201336. 10.1038/sj.cdd.4402187", "ArticleIdList": ["10.1038/sj.cdd.4402187", "17585337"]}, {"Citation": "Taylor CA, Zheng Q, Liu Z, Thompson JE. Role of p38 and JNK MAPK signalling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells. Mol Cancer. (2013) 12:35. 10.1186/1476-4598-12-35", "ArticleIdList": ["10.1186/1476-4598-12-35", "PMC3660295", "23638878"]}, {"Citation": "Issbr\u00fccker K, Marti HH, Hippenstiel S, Springmann G, Voswinckel R, Gaumann A, et al. . p38 MAP kinase\u2013a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. (2003) 17:262\u20134. 10.1096/fj.02-0329fje", "ArticleIdList": ["10.1096/fj.02-0329fje", "12490545"]}, {"Citation": "Chen YJ, Cheng YJ, Hung AC, Wu YC, Hou MF, Tyan YC, et al. . The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling. Gynecol Oncol. (2013) 131:734\u201343. 10.1016/j.ygyno.2013.10.012", "ArticleIdList": ["10.1016/j.ygyno.2013.10.012", "24145114"]}]}], "History": [{"Year": "2019", "Month": "3", "Day": "4"}, {"Year": "2019", "Month": "6", "Day": "4"}, {"Year": "2019", "Month": "7", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "12", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["31293977", "PMC6606729", "10.3389/fonc.2019.00545"]}}]}